Role of Contrast-Enhanced Ultrasound in Early Diagnosis of Psoriatic Arthritis

Dermatology ◽  
2010 ◽  
Vol 220 (1) ◽  
pp. 25-31 ◽  
Author(s):  
F.M. Solivetti ◽  
F. Elia ◽  
M. Teoli ◽  
C. De Mutiis ◽  
S. Chimenti ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Early Diagnosis ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced

scholarly journals Imaging appearance and role of CEUS of high flow priapism. A case report.

2019 ◽  
Vol 21 (3) ◽  
pp. 353
Author(s):  
Florin Elec ◽  
Tudor Moisoiu ◽  
Dan Burghelea ◽  
Razvan Zaro ◽  
Radu Badea
Keyword(s):  
Case Report ◽  
Early Diagnosis ◽  
Shear Wave ◽  
Ultrasound Examination ◽  
Shear Wave Elastography ◽  
High Flow ◽  
Contrast Enhanced Ultrasound ◽  
Imaging Appearance ◽  
Contrast Enhanced

High flow priapism caused by perineal trauma is a relatively rare disorder. Early diagnosis represents a mandatory condition for the therapeutic resolution. Ultrasound examination is affordable and a within reach method for diagnosis also in an emergency context. We present the case of a 56-year-old male patient with traumatic priapism which was subsequently investigated by contrast-enhanced ultrasound and shear wave elastography. This may be one of the first cases presented in the literature

The role of quantitation of real-time 3-dimensional contrast-enhanced ultrasound in detecting microvascular invasion: an in vivo study

2016 ◽  
Vol 41 (10) ◽  
pp. 1973-1979 ◽  
Author(s):  
Zhu Wang ◽  
Wei Wang ◽  
Guang-Jian Liu ◽  
Zheng Yang ◽  
Li-Da Chen ◽  
...  
Keyword(s):  
Real Time ◽  
Microvascular Invasion ◽  
In Vivo Study ◽  
Contrast Enhanced Ultrasound ◽  
3 Dimensional ◽  
Contrast Enhanced

The role of contrast-enhanced ultrasound in the classification of CT-indeterminate renal lesions

2016 ◽  
Vol 50 (6) ◽  
pp. 445-451 ◽  
Author(s):  
Jan Edenberg ◽  
Kaja Gløersen ◽  
Herzi Abdi Osman ◽  
Magne Dimmen ◽  
Geir V. Berg
Keyword(s):  
Contrast Enhanced Ultrasound ◽  
Renal Lesions ◽  
Contrast Enhanced

scholarly journals Role of contrast-enhanced ultrasound (CEUS) in the diagnosis and management of traumatic splenic injuries

2018 ◽  
Vol 21 (4) ◽  
pp. 315-327 ◽  
Author(s):  
Claudia Lucia Piccolo ◽  
Margherita Trinci ◽  
Antonio Pinto ◽  
Luca Brunese ◽  
Vittorio Miele
Keyword(s):  
Contrast Enhanced Ultrasound ◽  
Diagnosis And Management ◽  
Contrast Enhanced

scholarly journals Role of contrast-enhanced ultrasound in the evaluation of vascularization of hepatocellular carcinoma

2016 ◽  
Vol 2 (11) ◽  
Author(s):  
Francesco Loria ◽  
Giuseppe Loria ◽  
Salvatore Basile ◽  
Giuseppe Crea ◽  
Luciano Frosina ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced

scholarly journals Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Claudio Bonifati ◽  
Fulvia Elia ◽  
Dario Graceffa ◽  
Fabrizio Ceralli ◽  
Elisa Maiani ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Significant Proportion ◽  
Joint Inflammation ◽  
Joint Involvement ◽  
Contrast Enhanced Ultrasound ◽  
Continuous Therapy ◽  
Clinical Variables ◽  
Contrast Enhanced ◽  
Before And After ◽  
One Year

Background. We wanted to verify retrospectively the proportion of patients with psoriatic arthritis who were in remission after 1 year of continuous therapy with either etanercept or adalimumab. Remission was defined as the absence of both clinical and contrast-enhanced ultrasound (CEUS) findings suggestive of joint inflammation. Patients and Methods. The data of twenty-five patients with psoriatic arthritis were available for the clinical and CEUS evaluations before and after 1 year of continuous therapy with etanercept or adalimumab. The count of swollen (ACR66), tender (ACR68), and active inflamed joints (AJC) was used to measure the severity of joint involvement. PASI was used to score the severity of psoriasis. HAQ, DLQI, VAS pain, and VAS itching were administered to each patient before starting therapy and every 3 months, up to 1 year. Results. Eight (32%) out of twenty-five patients were in remission after 1 year of therapy with etanercept or adalimumab. A significant reduction of all clinical variables analysed was seen during the course of therapy. Conclusion. Although a significant proportion of patients achieved remission of arthritis after 1 year of effective anti-TNF therapy, the majority of them continued to have either clinical or CEUS findings suggestive of persistence of joint inflammation.

Sign in / Sign up

Export Citation Format

Share Document